Stock Scorecard
Stock Summary for Galectin Therapeutics Inc (GALT) - $2.18 as of 7/4/2025 1:10:04 AM EST
Total Score
5 out of 30
Safety Score
18 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GALT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GALT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GALT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for GALT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for GALT (18 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 7 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for GALT
Financial Details for GALT
Company Overview |
|
|---|---|
| Ticker | GALT |
| Company Name | Galectin Therapeutics Inc |
| Country | USA |
| Description | Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 8/18/2025 |
Stock Price History |
|
| Last Day Price | 2.18 |
| Price 4 Years Ago | 2.07 |
| Last Day Price Updated | 7/4/2025 1:10:04 AM EST |
| Last Day Volume | 239,497 |
| Average Daily Volume | 1,011,140 |
| 52-Week High | 3.90 |
| 52-Week Low | 0.73 |
| Last Price to 52 Week Low | 198.63% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.93 |
| Sector PE | 40.90 |
| 5-Year Average PE | -4.15 |
| Free Cash Flow Ratio | 18.17 |
| Industry Free Cash Flow Ratio | 17.71 |
| Sector Free Cash Flow Ratio | 32.91 |
| Current Ratio Most Recent Quarter | 0.08 |
| Total Cash Per Share | 0.12 |
| Book Value Per Share Most Recent Quarter | -1.81 |
| Price to Book Ratio | 207.70 |
| Industry Price to Book Ratio | 34.53 |
| Sector Price to Book Ratio | 30.76 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 121.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.60 |
| Analyst Buy Ratings | 0 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 63,292,000 |
| Market Capitalization | 137,976,560 |
| Institutional Ownership | 15.78% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.30% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -14.56% |
| Reported EPS 12 Trailing Months | -0.72 |
| Reported EPS Past Year | -0.19 |
| Reported EPS Prior Year | -0.76 |
| Net Income Twelve Trailing Months | -45,189,000 |
| Net Income Past Year | -47,047,000 |
| Net Income Prior Year | -41,066,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,431,000 |
| Total Cash Past Year | 15,120,000 |
| Total Cash Prior Year | 25,660,000 |
| Net Cash Position Most Recent Quarter | -3,382,000 |
| Net Cash Position Past Year | -69,989,000 |
| Long Term Debt Past Year | 85,109,000 |
| Long Term Debt Prior Year | 71,741,000 |
| Total Debt Most Recent Quarter | 10,813,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -103,070,000 |
| Total Stockholder Equity Prior Year | -60,241,000 |
| Total Stockholder Equity Most Recent Quarter | -113,984,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -37,351,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.59 |
| Free Cash Flow Past Year | -41,767,000 |
| Free Cash Flow Prior Year | -32,965,000 |
Options |
|
| Put/Call Ratio | 3.36 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.25 |
| MACD Signal | 0.26 |
| 20-Day Bollinger Lower Band | 0.88 |
| 20-Day Bollinger Middle Band | 1.56 |
| 20-Day Bollinger Upper Band | 2.23 |
| Beta | 0.55 |
| RSI | 54.75 |
| 50-Day SMA | 1.93 |
| 150-Day SMA | 1.90 |
| 200-Day SMA | 1.98 |
System |
|
| Modified | 7/3/2025 12:36:28 AM EST |